MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin

Introduction In this secondary analysis of the Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) trial, we evaluated what demographic and clinical factors were associated with reduction in weight. We also assessed the effects of acarbose and metformin treatment on weig...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Na Wang, Jin-Ping Zhang, Xiao-Yan Xing, Zhao-Jun Yang, Bo Zhang, Xin Wang, Wen-Ying Yang
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2019
Materias:	weight loss type 2 diabetes metformin acarbose march trial Medicine R
Acceso en línea:	https://doaj.org/article/f47e2d59273c4b97bcd307641ba863bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f47e2d59273c4b97bcd307641ba863bb
record_format	dspace
spelling	oai:doaj.org-article:f47e2d59273c4b97bcd307641ba863bb2021-12-02T16:58:44ZMARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin1734-19221896-915110.5114/aoms.2018.75255https://doaj.org/article/f47e2d59273c4b97bcd307641ba863bb2019-03-01T00:00:00Zhttps://www.archivesofmedicalscience.com/MARCH-factors-associated-with-weight-loss-in-patients-with-newly-diagnosed-type-2,70467,0,2.htmlhttps://doaj.org/toc/1734-1922https://doaj.org/toc/1896-9151Introduction In this secondary analysis of the Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) trial, we evaluated what demographic and clinical factors were associated with reduction in weight. We also assessed the effects of acarbose and metformin treatment on weight reduction. Material and methods We analyzed the demographic and clinical laboratory values from the 784 patients with type 2 diabetes of the MARCH study who were treated for 48 weeks with acarbose or metformin. We determined the association of the different parameters with a weight reduction of ≥ 2 kg in patients using univariate and multivariate analysis. Results In patients treated with acarbose, males were less likely than females to lose ≥ 2 kg of weight (p = 0.025). Higher baseline HbA 1c levels and lower decreases from baseline in fasting plasma glucose (FPG) levels after 48 weeks of treatment were negatively associated with losing ≥ 2 kg of weight (both, p < 0.05). Higher baseline glucagon AUC was also positively associated with reducing weight by ≥ 2 kg (p = 0.010). In patients treated with metformin, change from baseline in whole body insulin sensitivity increased the odds of having a weight reduction of ≥ 2 kg (p = 0.014). Conclusions This study found that for both acarbose and metformin, control of FPG significantly impacted weight loss. Baseline AUC for glucagon in patients treated with acarbose and an increase of whole body insulin sensitivity after 48 weeks of treatment with metformin were important factors for weight reduction.Na WangJin-Ping ZhangXiao-Yan XingZhao-Jun YangBo ZhangXin WangWen-Ying YangTermedia Publishing Housearticleweight losstype 2 diabetesmetforminacarbosemarch trialMedicineRENArchives of Medical Science, Vol 15, Iss 2, Pp 309-320 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	weight loss type 2 diabetes metformin acarbose march trial Medicine R
spellingShingle	weight loss type 2 diabetes metformin acarbose march trial Medicine R Na Wang Jin-Ping Zhang Xiao-Yan Xing Zhao-Jun Yang Bo Zhang Xin Wang Wen-Ying Yang MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
description	Introduction In this secondary analysis of the Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) trial, we evaluated what demographic and clinical factors were associated with reduction in weight. We also assessed the effects of acarbose and metformin treatment on weight reduction. Material and methods We analyzed the demographic and clinical laboratory values from the 784 patients with type 2 diabetes of the MARCH study who were treated for 48 weeks with acarbose or metformin. We determined the association of the different parameters with a weight reduction of ≥ 2 kg in patients using univariate and multivariate analysis. Results In patients treated with acarbose, males were less likely than females to lose ≥ 2 kg of weight (p = 0.025). Higher baseline HbA 1c levels and lower decreases from baseline in fasting plasma glucose (FPG) levels after 48 weeks of treatment were negatively associated with losing ≥ 2 kg of weight (both, p < 0.05). Higher baseline glucagon AUC was also positively associated with reducing weight by ≥ 2 kg (p = 0.010). In patients treated with metformin, change from baseline in whole body insulin sensitivity increased the odds of having a weight reduction of ≥ 2 kg (p = 0.014). Conclusions This study found that for both acarbose and metformin, control of FPG significantly impacted weight loss. Baseline AUC for glucagon in patients treated with acarbose and an increase of whole body insulin sensitivity after 48 weeks of treatment with metformin were important factors for weight reduction.
format	article
author	Na Wang Jin-Ping Zhang Xiao-Yan Xing Zhao-Jun Yang Bo Zhang Xin Wang Wen-Ying Yang
author_facet	Na Wang Jin-Ping Zhang Xiao-Yan Xing Zhao-Jun Yang Bo Zhang Xin Wang Wen-Ying Yang
author_sort	Na Wang
title	MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
title_short	MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
title_full	MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
title_fullStr	MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
title_full_unstemmed	MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
title_sort	march: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
publisher	Termedia Publishing House
publishDate	2019
url	https://doaj.org/article/f47e2d59273c4b97bcd307641ba863bb
work_keys_str_mv	AT nawang marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin AT jinpingzhang marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin AT xiaoyanxing marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin AT zhaojunyang marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin AT bozhang marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin AT xinwang marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin AT wenyingyang marchfactorsassociatedwithweightlossinpatientswithnewlydiagnosedtype2diabetestreatedwithacarboseormetformin
_version_	1718382304663961600

MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin

Ejemplares similares